Covid Reference

Page 47

Epidemiology

|

47

implementing widespread case isolation (Wells 2020), was expected to result in a devastating impact of COVID-19 on African countries. These predictions have not materialized. There has been no COVID-19 explosion in Africa, although seroprevalence data are comparable to those from European countries like France, Italy and Spain. However, the burden and outcomes associated with COVID-19 shows substantial variations across African countries [Twahirwa 2020]. (There is no ‘one’ Africa!) In April-June 2020, the crude prevalence of anti–SARS-CoV-2 IgG among blood donors in Kenya was 5,6% (174/3098). It was highest in urban counties, Mombasa (8,0%), Nairobi (7,3%) and Kisumu (5,5%) (Uyoga 2020). Of note, Kenya had reported only 341 deaths by the end of that period. The authors conclude that the sharp contrast between the reported COVID-19 cases and deaths suggests that the disease might be attenuated in Africa. Has time come to hypothesize an “African demographic exception”? In the Democratic Republic of the Congo and Malawi, for instance, only 2-3% of the population is older than 65 years (Kalk 2020), in sharp contrast to Europe at 20,5% or Lombardy at 26%. If > 65-year-old SARS-CoV-2 infected individuals are 100 times more likely to die from COVID-19 than a 25-year-old, we should expect two different epidemics. Simply, the age pyramid might make the difference.

The SARS-CoV-2 pandemic: Past and Future Natural course of a pandemic The COVID-19 epidemic started in Wuhan, in Hubei province, China, and spread within 30 days from Hubei to the rest of mainland China, to neighboring countries (in particular, South Korea, Hong Kong and Singapore) and west to Iran, Europe and the Americas. The first huge outbreaks occurred in regions with cold winters (Wuhan, Iran, Northern Italy, the Alsace region in France). Fifty years ago, the course of the COVID-19 pandemic would have been different, with slower global spread but higher burden due to limited diagnostic and therapeutic capacities and no option of nation-wide lockdowns (see also a report of the influenza pandemics in 1957 and 1968: Honigsbaum 2020). According to one (controversial) simulation, in the absence of effective treatment and with a mortality rate of around 0,5%, without interventions COVID19 would have resulted in 7 billion infections and 40 million deaths globally during the first year (Patrick 2020). The peak in mortality (daily deaths) would have been observed approximately 3 months after the beginning of local epidemics. Another model predicted that 80% of the US population COVID Reference ENG 006.9


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

References

1hr
pages 497-554

Management

10min
pages 491-496

Diagnosis and classification

11min
pages 484-490

Transplantation

4min
pages 472-473

Transmission

4min
pages 482-483

Pathophysiology and immunopathology

4min
pages 480-481

Natural course and risk factors for complications

2min
page 479

Epidemiology of COVID-19 in children

2min
page 478

Cancer

8min
pages 468-471

Immunosuppression (other than HIV

3min
pages 466-467

HIV infection

6min
pages 463-465

COPD and smoking

4min
pages 461-462

Hypertension and cardiovascular co-morbidities

14min
pages 452-458

Diabetes mellitus

4min
pages 459-460

References

6min
pages 447-451

Special situations in severe COVID-19

3min
pages 445-446

References

25min
pages 429-440

Spotlight: The situation in a German COVID-19 hospital

4min
pages 443-444

Outlook and Recommendations

1min
page 428

4. Immunomodulators

19min
pages 415-424

Other treatments for COVID-19 (with unknown or unproven mechanisms of action

5min
pages 425-427

3. Monoclonal Antibodies and Convalescent Plasma

13min
pages 408-414

2. Various antiviral agents

5min
pages 405-407

1. Inhibitors of the viral RNA synthesis

11min
pages 399-404

Monitoring, treatment options

3min
pages 391-392

Studies with objectifiable tests

3min
pages 389-390

Reactivations, reinfections

2min
page 366

Outcome

27min
pages 352-365

Clinical classification

1min
page 351

Laboratory findings

6min
pages 347-350

References

21min
pages 324-332

Asymptomatic cases

4min
pages 334-335

Radiology

6min
pages 321-323

Incubation period

1min
page 333

Symptoms

21min
pages 336-346

Diagnosis

36min
pages 303-320

References

55min
pages 277-302

Outlook

5min
pages 272-276

Single Vaccines

24min
pages 247-261

Coming vaccines

8min
pages 267-271

Special Topics

9min
pages 241-246

Approved Vaccines

2min
pages 223-224

References

21min
pages 211-222

Outlook

1min
page 210

Transmission

1min
page 187

Epidemiology

11min
pages 175-186

Summary – 13 February

1min
page 173

Genomic Structure and Variation

4min
pages 164-166

References

8min
pages 167-172

Origin and Evolution

4min
pages 158-159

Introduction

1min
page 174

History

4min
pages 154-155

References

20min
pages 136-152

Conclusion

1min
page 135

Introduction

31min
pages 117-133

Containment or mitigation of COVID-19?

1min
page 134

References

40min
pages 99-116

Outlook

1min
page 98

Prevention

3min
pages 96-97

End of Quarantine

1min
page 95

Transmission Event

26min
pages 82-94

References

31min
pages 54-68

Summary

1min
page 69

Routes of Transmission

16min
pages 73-81

Outlook

3min
pages 52-53

The 2020 Lockdowns

7min
pages 48-51

Person-to-person transmission

2min
page 72

Special Aspects of the Pandemic

15min
pages 38-46

The SARS-CoV-2 pandemic: Past and Future

2min
page 47
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.